Sangamo Therapeutics Stock Investor Sentiment

SGMO Stock  USD 1.88  0.08  4.08%   
About 71% of Sangamo Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Sangamo Therapeutics suggests that many traders are alarmed. Sangamo Therapeutics' investing sentiment overview a quick insight into current market opportunities from investing in Sangamo Therapeutics. Many technical investors use Sangamo Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
  

Sangamo Therapeutics Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Sangamo Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
2 days ago at news.google.com         
GSA Capital Partners LLP Trims Stock Holdings in Sangamo Therapeutics, Inc. - MarketBeat
Google News at Macroaxis
few days ago at simplywall.st         
Analysts Just Made A Massive Upgrade To Their Sangamo Therapeutics, Inc. Forecasts
Simply Wall St News at Macroaxis
few days ago at businesswire.com         
Sangamo Therapeutics Announces U.S. FDA Clearance of IND Application for ST-503 for the Treatment of...
businesswire News
few days ago at seekingalpha.com         
Sangamo stock climbs 12 percent post-market on FDA update for ST-503
seekingalpha News
over a week ago at thelincolnianonline.com         
HC Wainwright Has Bullish Outlook for SGMO FY2028 Earnings
news
over a week ago at thelincolnianonline.com         
Sangamo Therapeutics Stock Rating Upgraded by StockNews.com
news
over a week ago at finance.yahoo.com         
Sangamo Therapeutics Third Quarter 2024 Earnings Beats Expectations
Yahoo News
over a week ago at simplywall.st         
Sangamo Therapeutics Third Quarter 2024 Earnings Beats Expectations
Simply Wall St News at Macroaxis
over a week ago at thelincolnianonline.com         
Sangamo Therapeutics Trading Down 6.6 percent Time to Sell?
news
over a week ago at gurufocus.com         
Sangamo Therapeutics Inc Q3 2024 Earnings Call Highlights Strategic Advances and ...
Gurufocus Stories at Macroaxis
over a week ago at investing.com         
Earnings call Sangamo Therapeutics reports progress in gene therapies
Investing News at Macroaxis
over a week ago at insidermonkey.com         
Sangamo Therapeutics, Inc. Q3 2024 Earnings Call Transcript
insidermonkey News
over a week ago at seekingalpha.com         
Sangamo Therapeutics files for mixed shelf offering
seekingalpha News
over a week ago at seekingalpha.com         
Sangamo Therapeutics GAAP EPS of 0.04 beats by 0.08, revenue of 49.41M beats by 24.34M
seekingalpha News
over a week ago at seekingalpha.com         
Sangamo Therapeutics Q3 beats propel stock 5 percent higher
seekingalpha News
Far too much social signal, news, headlines, and media speculation about Sangamo Therapeutics that are available to investors today. That information is available publicly through Sangamo media outlets and privately through word of mouth or via Sangamo internal channels. However, regardless of the origin, that massive amount of Sangamo data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Sangamo Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Sangamo Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Sangamo Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Sangamo Therapeutics alpha.

Sangamo Therapeutics Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Sangamo Therapeutics, Inc. Short Interest Update - MarketBeat
08/30/2024
2
Disposition of 5474 shares by Dubois-stringfellow Nathalie of Sangamo Therapeutics at 1.13 subject to Rule 16b-3
09/25/2024
3
Acquisition by Horn Margaret A of 13900 shares of Sangamo Therapeutics subject to Rule 16b-3
10/15/2024
4
Insider Trading
10/18/2024
5
Whats Going On With Sangamo Therapeutics Shares Tuesday
10/22/2024
6
Merck acquires cancer drug startup Elevidys ex-US sales rise
10/23/2024
7
individual investors who own 55 percent along with institutions invested in Sangamo Therapeutics, Inc. saw increase in their holdings value last week
11/01/2024
8
Myriad Genetics Q3 Earnings and Revenues Surpass Estimates
11/07/2024
9
Sangamo Therapeutics GAAP EPS of 0.04 beats by 0.08, revenue of 49.41M beats by 24.34M
11/12/2024
10
Sangamo Therapeutics Inc Q3 2024 Earnings Call Highlights Strategic Advances and ...
11/13/2024
11
Sangamo Therapeutics Third Quarter 2024 Earnings Beats Expectations
11/15/2024
12
Sangamo stock climbs 12 percent post-market on FDA update for ST-503
11/19/2024
When determining whether Sangamo Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sangamo Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sangamo Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sangamo Therapeutics Stock:
Check out Sangamo Therapeutics Hype Analysis, Sangamo Therapeutics Correlation and Sangamo Therapeutics Performance.
To learn how to invest in Sangamo Stock, please use our How to Invest in Sangamo Therapeutics guide.
You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sangamo Therapeutics. If investors know Sangamo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sangamo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.24)
Revenue Per Share
0.066
Quarterly Revenue Growth
(0.95)
Return On Assets
(0.58)
Return On Equity
(1.94)
The market value of Sangamo Therapeutics is measured differently than its book value, which is the value of Sangamo that is recorded on the company's balance sheet. Investors also form their own opinion of Sangamo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Sangamo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sangamo Therapeutics' market value can be influenced by many factors that don't directly affect Sangamo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sangamo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sangamo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sangamo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.